Find additional information about AlloSure below.
Healthcare Provider Brochure
Donor-Derived Cell-Free DNA (dd-cfDNA): An Emerging Biomarker of Allograft Health in Solid Organ Transplant Recipients. Download brochure.
Bloom RD., Bromberg JS, Poggio E, et al. Cell-free DNA and active rejection in kidney allografts. J Am SocNephrol. 2017.
Bromberg JS, Brennan DC, Poggio E, et al. Biological variation of donor-derived cell-free DNA in renal transplant recipients: clinical implications. J Appl Lab Med. 2017;1(5).
Grskovic M, Hiller DJ, Eubank LA, et al. Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients. J Mol Diagn. 2016;18:890-902
Donor-Derived Cell-Free DNA is a Dynamic Biomarker of Active Rejection in Kidney Allografts. View poster.
Donor-Derived Cell-Free DNA Normal Range and Biological Variation Defined in a Reference Population. View poster.
Donor-Derived Cell-free DNA in Plasma increases with Rejection and Decreases after Treatment in Kidney Transplant Recipients. View poster.
Donor-Derived Cell-Free DNA Identifies Antibody-Mediated Rejection With Graft Injury in DSA-Positive Kidney Transplant Recipients. View poster.
Donor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients. View presentation.
What you should know about using AlloSure
+ Samples collected in Streck Cell-Free DNA BCT® tubes with no additional processing or preparation required before shipping
+ Samples are run in-house at CareDx’s CLIA-certified and CAP-accredited clinical laboratory
+ Results reported within 72 hours of blood draw
AlloSure Performance Characteristics
For further information, or to order AlloSure, please contact CareDx: (888) 255-6627 or .